Impact of SARS-CoV-2 infection on patients with cancer : retrospective and transversal studies in Spanish population

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorGarde Noguera, Javier
dc.contributor.authorFernández Murga, María Leonor
dc.contributor.authorGiner Bosch, Vicent
dc.contributor.authorDomínguez Márquez, María Victoria
dc.contributor.authorGarcía Sánchez, José
dc.contributor.authorSoler Cataluña, Juan José
dc.contributor.otherProducción Científica UCH 2020
dc.contributor.otherUCH. Departamento de Medicina y Cirugía
dc.date2020
dc.date.accessioned2021-05-12T04:00:27Z
dc.date.available2021-05-12T04:00:27Z
dc.date.issued2020-11-25
dc.descriptionEste artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2072-6694/12/12/3513
dc.descriptionEn este artículo también participan: Franscica López Chuliá, Beatriz Honrubia, Nuria Piera y Antonio Llombart-Cussac.
dc.description.abstractBackground: Studies of patients with cancer a ected by coronavirus disease 2019 (COVID-19) are needed to assess the impact of the disease in this sensitive population, and the influence of di erent cancer treatments on the COVID-19 infection and seroconversion. Material and Methods: We performed a retrospective analysis of all patients hospitalized with RT-PCR positive for COVID-19 in our region to assess the prevalence of cancer patients and describe their characteristics and evolution (Cohort 1). Concurrently, a transversal study was carried out in patients on active systemic cancer treatment for symptomatology and seroprevalence (IgG/IgM by ELISA-method) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Cohort 2). Results: A total of 215 patients (Cohort 1) were admitted to hospital with a confirmed COVID-19 infection between February 28 and April 30, 2020, and 17 died (7.9%). A medical record of cancer was noted in 43 cases (20%), 6 of them required Intensive care unit ICU attention (14%), and 7 died (16%). There were thirty-six patients (83%) who tested IgG/IgM positive for SARS-CoV-2. Patients on immunosuppressive therapies presented a lower ratio of seroconversion (40% vs. 8%; p = 0.02). In Cohort 2, 166 patients were included in a symptoms-survey and tested for SARS-CoV-2. Any type of potential COVID-19-related symptom was referred up to 67.4% of patients (85.9% vs. 48.2% vs. 73.9%, for patients on chemotherapy, immunotherapy and targeted therapies respectively, p < 0.05). The seroprevalence ratio was 1.8% for the whole cohort with no significant di erences by patient or treatment characteristics. Conclusion: Patients with cancer present higher risks for hospital needs for COVID-19 infection. The lack of SARS-CoV-2 seroconversion may be a concern for patients on immunosuppressive therapies. Patients receiving systematic therapies relayed a high rate of potentially COVID-19-related symptoms, particularly those receiving chemotherapy. However, the seroconversion rate remains low and in the range of general population.
dc.formatapplication/pdf
dc.identifier.citationGarde-Noguera, J., Fernández-Murga, M.L., Giner-Bosch, V., Dominguez-Márquez, V., Sánchez, J.G., Soler-Cataluña, J.J. et al. (2020). Impact of SARS-CoV-2 infection on patients with cancer: retrospective and transversal studies in Spanish population. Cancers, vol. 12, i. 12 (25 nov.), art. 3513. DOI: https://doi.org/10.3390/cancers12123513
dc.identifier.doihttps://doi.org/10.3390/cancers12123513
dc.identifier.issn2072-6694 (Electrónico).
dc.identifier.urihttp://hdl.handle.net/10637/12598
dc.language.isoes
dc.language.isoen
dc.publisherMDPI
dc.relationEste trabajo de investigación ha sido financiado parcialmente por el Ministerio de Ciencia e Innovación del Gobierno de España bajo la beca PID2019-110442GB-I00.
dc.relation.ispartofCancers, vol. 12, n. 12.
dc.relation.projectIDPID2019-110442GB-I00
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectCáncer - Quimioterapia.
dc.subjectCáncer - Pacientes.
dc.subjectCoronavirus.
dc.subjectCoronaviruses.
dc.subjectCancer - Immunotherapy.
dc.subjectCancer - Chemotherapy.
dc.subjectCOVID-19 - España.
dc.subjectCOVID-19 (Disease) - Spain.
dc.subjectCancer - Patients.
dc.subjectCáncer - Inmunoterapia.
dc.subjectSARS-CoV-2 (Virus)
dc.titleImpact of SARS-CoV-2 infection on patients with cancer : retrospective and transversal studies in Spanish population
dc.typeArtículo
dspace.entity.typePublicationes
relation.isAuthorOfPublicationfda7b4b5-b05c-4175-8e4a-822d38906d87
relation.isAuthorOfPublication.latestForDiscoveryfda7b4b5-b05c-4175-8e4a-822d38906d87

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Impact_Garde_CANCERS_2020.pdf
Size:
730.81 KB
Format:
Adobe Portable Document Format